Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKBYWI)

Drug Name
Trifluoperazine Drug Info
Synonyms
Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
Indication
Disease Entry ICD 11 Status REF
Anxiety Approved [1]
Schizophrenia 6A20 Approved [2]
Therapeutic Class
Antipsychotic Agents
Cross-matching ID
PubChem CID
5566
ChEBI ID
CHEMBL422
CAS Number
CAS 117-89-5
TTD Drug ID
DMKBYWI
VARIDT Drug ID
DR00664
INTEDE Drug ID
DR1641
ACDINA Drug ID
D00703

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Calmodulin (CALM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Halofantrine DMOMK1V Malaria 1F40-1F45 Approved [12]
Aprindine DMBXWU8 Cardiac arrhythmias BC9Z Approved [13]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [14]
2-Methyl-2,4-Pentanediol DMD45CU Discovery agent N.A. Investigative [14]
MYRISTIC ACID DMYX0BL Discovery agent N.A. Investigative [15]
Cacodylate Ion DMK4XLD Discovery agent N.A. Investigative [14]
2-Methyl-2-Propanol DMHM5GJ Discovery agent N.A. Investigative [14]
N-Trimethyllysine DMZQXLS Discovery agent N.A. Investigative [14]
Calmidazolium DM5ZTJL Huntington disease 8A01.10 Investigative [16]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [17]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [18]
Methotrexate DM2TEOL Anterior urethra cancer Approved [4]
Folic Acid DMEMBJC Colorectal carcinoma Approved [19]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [4]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [4]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [20]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [4]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [21]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [23]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [24]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [26]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [27]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [28]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [29]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [30]
Verapamil DMA7PEW Angina pectoris BA40 Approved [31]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Dimethylaniline oxidase 2 (FMO2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Angina pectoris BA40 Approved [6]
Ethionamide DM8K3EI Pulmonary tuberculosis 1B10.Z Approved [33]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [33]
Drug(s) Affected By Flavin-containing monooxygenase 2 (FMO2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Angina pectoris BA40 Approved [6]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [34]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [35]
Testosterone enanthate DMB6871 N. A. N. A. Approved [36]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [37]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [38]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [39]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [40]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [41]
PMID28454500-Compound-96 DM2A75P N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [42]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [43]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [44]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [45]
Cepharanthine DM9Y5JB N. A. N. A. Approved [46]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [47]
Clozapine DMFC71L Schizophrenia 6A20 Approved [48]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [49]
Olanzapine DMPFN6Y Bipolar depression Approved [48]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By E3 ubiquitin-protein ligase parkin (PRKN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Emtricitabine DMBMUWZ Hepatitis virus infection 1E50-1E51 Approved [50]
Tubocurarine DMBZIVP Anaesthesia 9A78.6 Approved [51]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [37]
Ethanol DMDRQZU Chronic pain MG30 Approved [52]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [53]
Methamphetamine DMPM4SK Anxiety Approved [54]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [55]
Arsenic DMTL2Y1 N. A. N. A. Approved [56]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [38]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Stonin-2 (STON2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [57]
Leflunomide DMR8ONJ Arthritis FA20 Approved [58]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [59]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [60]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [61]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [62]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [63]
Urethane DM7NSI0 N. A. N. A. Phase 4 [64]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [41]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(3) dopamine receptor (DRD3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Haloperidol DM96SE0 Delirium Approved [66]
Clozapine DMFC71L Schizophrenia 6A20 Approved [67]
Risperidone DMN6DXL Bipolar I disorder Approved [68]
Folic Acid DMEMBJC Colorectal carcinoma Approved [69]
Methamphetamine DMPM4SK Anxiety Approved [70]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [71]
Droperidol DM0DXA8 Nausea MD90 Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [8]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(4) dopamine receptor (DRD4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [72]
Haloperidol DM96SE0 Delirium Approved [73]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [37]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [74]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [75]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [61]
Methamphetamine DMPM4SK Anxiety Approved [76]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [77]
Droperidol DM0DXA8 Nausea MD90 Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(2) dopamine receptor (DRD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Droperidol DM0DXA8 Nausea MD90 Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Zuclopenthixol DMKYD5N Schizophrenia 6A20 Approved [8]
Meglitinides DM1OFHN Type-2 diabetes 5A11 Approved [78]
Sulpiride DMF54ZG Schizophrenia 6A20 Approved [79]
Risperidone DMN6DXL Bipolar I disorder Approved [80]
Olanzapine DMPFN6Y Bipolar depression Approved [81]
Methamphetamine DMPM4SK Anxiety Approved [82]
Bromocriptine DMVE3TK Acromegaly 5A60.0 Approved [83]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [84]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calmodulin (CALM) TTV3NH6 CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN Inhibitor [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [5]
Dimethylaniline oxidase 2 (FMO2) DEIASEZ FMO2_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [7]
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Drug Response [8]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Drug Response [8]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Drug Response [8]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Protein Interaction/Cellular Processes [9]
Flavin-containing monooxygenase 2 (FMO2) OTUJUL9S FMO2_HUMAN Biotransformations [6]
Stonin-2 (STON2) OT01JHHE STON2_HUMAN Gene/Protein Processing [10]
UDP-glucuronosyltransferase 1A4 OT4PU620 UD14_HUMAN Gene/Protein Processing [11]

References

1 Trifluoperazine FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
5 Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles
6 Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
7 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. Cell Chem Biol. 2017 Apr 20;24(4):471-480.e4. doi: 10.1016/j.chembiol.2017.03.005. Epub 2017 Mar 30.
10 Stonin 2 activates lysosomal-mTOR axis for cell survival in oral cancer. Toxicol In Vitro. 2023 Apr;88:105561. doi: 10.1016/j.tiv.2023.105561. Epub 2023 Jan 23.
11 Assessment of the inhibition potential of Licochalcone A against human UDP-glucuronosyltransferases. Food Chem Toxicol. 2016 Apr;90:112-22.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
14 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
15 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16 Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.
17 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
18 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
19 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
20 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
21 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
22 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
23 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
25 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
26 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
27 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
28 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
29 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
30 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
31 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
32 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
33 Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
34 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
35 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
36 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
37 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
38 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
39 Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics. Pharmacogenet Genomics. 2005 Apr;15(4):245-56. doi: 10.1097/01213011-200504000-00008.
40 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
41 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
42 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
43 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
44 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
45 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
46 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
47 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
48 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
49 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
50 Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicol Sci. 2019 Dec 1;172(2):445-456. doi: 10.1093/toxsci/kfz203.
51 Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
52 Silibinin inhibits ethanol- or acetaldehyde-induced ferroptosis in liver cell lines. Toxicol In Vitro. 2022 Aug;82:105388. doi: 10.1016/j.tiv.2022.105388. Epub 2022 May 18.
53 Induction of parkin expression in the presence of oxidative stress. Eur J Neurosci. 2006 Sep;24(5):1366-72. doi: 10.1111/j.1460-9568.2006.04998.x.
54 Involvement of C/EBP-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis. Toxicol Lett. 2019 Sep 15;312:11-21. doi: 10.1016/j.toxlet.2019.05.003. Epub 2019 May 3.
55 Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.
56 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
57 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
58 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
59 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
60 The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
61 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
62 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
63 Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
64 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
65 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
66 The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
67 Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010 Jun;10(3):200-18. doi: 10.1038/tpj.2009.65. Epub 2009 Dec 22.
68 A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J. 2009 Dec;9(6):404-10. doi: 10.1038/tpj.2009.26. Epub 2009 Jun 9.
69 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
70 Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci. 2009 Nov 25;29(47):14734-40. doi: 10.1523/JNEUROSCI.3765-09.2009.
71 Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry. 2009 Oct;166(10):1170-7. doi: 10.1176/appi.ajp.2009.08121801. Epub 2009 Sep 1.
72 Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005 Nov;115(11):1539-47. doi: 10.1080/00207450590957863.
73 Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
74 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
75 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
76 Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):120-4. doi: 10.1002/ajmg.b.30024.
77 Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?. Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 5;144B(8):1034-41. doi: 10.1002/ajmg.b.30540.
78 Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008 Apr;197(2):229-35. doi: 10.1007/s00213-007-1029-z. Epub 2007 Dec 6.
79 Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
80 Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.
81 Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
82 A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
83 Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
84 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.